Francesca Fiorelli
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Francesca Fiorelli has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Alessandro Galluzzo
Department of Cardiology, Rivoli Hospital , Via Rivalta 29, Rivoli, Turin 10098
1 shared publication - Geza Halasz
Division of Cardiology, Cardio-Thoracic and Vascular Department, Azienda Ospedaliera San Camillo Forlanini, 00152 Rome, Italy
1 shared publication - Giulia Montrasio
Inherited Cardiovascular Diseases Unit, Barts Heart Centre, St. Bartholomew’s Hospital, London EC1A 7BS, UK
1 shared publication - Giuseppe Uccello
Division of Cardiology, “A. Manzoni” Hospital—ASST Lecco, 23900 Lecco, Italy
1 shared publication - Luca Monzo
Université de Lorraine, INSERM, Centre d'Investigation Clinique Plurithématique 1433, Inserm U1116, CHRU de Nancy and F-CRIN INI-CRCT , 5 rue du Morvan, 54500 Vandœuvre-lès-Nancy
1 shared publication - Massimiliano Camilli
Department of Cardiovascular and Pulmonary Sciences, Catholic University of the Sacred Heart, Rome, Italy
1 shared publication
Latest Publications
- Open Access
Multimodality Imaging in Sarcomeric Hypertrophic Cardiomyopathy: Get It Right…on Time
Hypertrophic cardiomyopathy (HCM) follows highly variable paradigms and disease-specific patterns of progression towards heart failure, arrhythmias and sudden cardiac death. Therefore, a generalized standard approach, shared with other cardiomyopathies, can be misleading in this setting. A multimodality imaging approach facilitates differential diagnosis of phenocopies and improves clinical and therapeutic management of the disease. However, only a profound knowledge of the progression patterns, including clinical features and imaging data, enables an appropriate use of all these resources in clinical practice. Combinations of various imaging tools and novel techniques of artificial intelligence have a potentially relevant role in diagnosis, clinical management and definition of prognosis. Nonetheless, several barriers persist such as unclear appropriate timing of imaging or universal standardization of measures and normal reference limits. This review provides an overview of the current knowledge on multimodality imaging and potentialities of novel tools, including artificial intelligence, in the management of patients with sarcomeric HCM, highlighting the importance of specific “red alerts” to understand the phenotype–genotype linkage.
Open AccessMultimodality Imaging in Sarcomeric Hypertrophic Cardiomyopathy: Get It Right…on Time
Hypertrophic cardiomyopathy (HCM) follows highly variable paradigms and disease-specific patterns of progression towards heart failure, arrhythmias and sudden cardiac death. Therefore, a generalized standard approach, shared with other cardiomyopathies, can be misleading in this setting. A multimodality imaging approach facilitates differential diagnosis of phenocopies and improves clinical and therapeutic management of the disease. However, only a profound knowledge of the progression patterns, including clinical features and imaging data, enables an appropriate use of all these resources in clinical practice. Combinations of various imaging tools and novel techniques of artificial intelligence have a potentially relevant role in diagnosis, clinical management and definition of prognosis. Nonetheless, several barriers persist such as unclear appropriate timing of imaging or universal standardization of measures and normal reference limits. This review provides an overview of the current knowledge on multimodality imaging and potentialities of novel tools, including artificial intelligence, in the management of patients with sarcomeric HCM, highlighting the importance of specific “red alerts” to understand the phenotype–genotype linkage.